Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Cisplatin

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03277924Phase 1/2Completed

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Showing all 1 trials

Research Network

Common Treatments

  • Cisplatin1
  • Ifosfamide1
  • Methotrexate1
  • Dacarbazine1
  • Doxorubicin1

Active Sponsors

  • Asoc Grupo Espanol De Investigacion En Sarcomas1
  • Grupo Espanol de Investigacion en Sarcomas1

Top Investigators

Related Conditions

  • Soft Tissue Sarcoma1
  • Bone Sarcoma1

Activity Timeline